Clinical Trial Update: Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC [NA]

View source ↗

Summary

Clinical trial NCT07350824 evaluates whether minimal residual disease can predict postoperative recurrence in hepatocellular carcinoma and assesses adjuvant PD-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PD-1 inhibitor

Snippet

Sponsor: Tongji Hospital | Conditions: HCC, Minimal Residual Disease | NA | Status: NOT_YET_RECRUITING